IE
GENB

Israel Englander’s Generate Biomedicines GENB Stock Holding History

Israel Englander’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$370K Sell
21,926
-354,967
-94% -$4.84M ﹤0.01% 4980
2026
Q1 		$4.71M Buy
+376,893
New +$4.6M ﹤0.01% 3015

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Israel Englander's GENB Position: Q2 2026 in Review

Israel Englander reduced its Generate Biomedicines (GENB) stake by 94% in Q2 2026, selling an estimated $4.84M and leaving 21,926 shares worth $370K. The position accounts for ﹤0.01% of the portfolio, ranked #4980.

Israel Englander first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.71M in Q1 2026. 85 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Israel Englander held 21,926 shares of Generate Biomedicines worth $370K as of Q2 2026.
  • Israel Englander sold 354,967 Generate Biomedicines shares in Q2 2026, an estimated $4.84M.
  • Generate Biomedicines made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4980 holding.
  • Israel Englander first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • Israel Englander's Generate Biomedicines position peaked at $4.71M in Q1 2026.
  • 85 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.